Canada
· Delayed Price · Currency is CAD Knight Therapeutics Statistics
Total Valuation
Knight Therapeutics has a market cap or net worth of CAD 580.61 million. The enterprise value is 451.04 million.
| Market Cap | 580.61M |
| Enterprise Value | 451.04M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Knight Therapeutics has 101.33 million shares outstanding. The number of shares has decreased by -7.58% in one year.
| Shares Outstanding | 101.33M |
| Shares Change (YoY) | -7.58% |
| Shares Change (QoQ) | -2.45% |
| Owned by Insiders (%) | 22.26% |
| Owned by Institutions (%) | 12.32% |
| Float | 53.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 75.39 |
| PS Ratio | 1.81 |
| PB Ratio | 0.76 |
| P/FCF Ratio | 9.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.61, with an EV/FCF ratio of 7.42.
| EV / Earnings | -25.86 |
| EV / Sales | 1.36 |
| EV / EBITDA | 8.61 |
| EV / EBIT | 132.78 |
| EV / FCF | 7.42 |
Financial Position
The company has a current ratio of 3.33, with a Debt / Equity ratio of 9.20.
| Current Ratio | 3.33 |
| Quick Ratio | 2.47 |
| Debt / Equity | 9.20 |
| Debt / EBITDA | 1.34 |
| Debt / FCF | 1.15 |
| Interest Coverage | 0.28 |
Financial Efficiency
Return on equity (ROE) is -2.21% and return on invested capital (ROIC) is 0.24%.
| Return on Equity (ROE) | -2.21% |
| Return on Assets (ROA) | 0.21% |
| Return on Capital (ROIC) | 0.24% |
| Revenue Per Employee | 458,215 |
| Profits Per Employee | -24,061 |
| Employee Count | 725 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | -6.74M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.46% in the last 52 weeks. The beta is 0.49, so Knight Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +16.46% |
| 50-Day Moving Average | 5.79 |
| 200-Day Moving Average | 5.43 |
| Relative Strength Index (RSI) | 51.44 |
| Average Volume (20 Days) | 47,096 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Knight Therapeutics had revenue of CAD 332.21 million and -17.44 million in losses. Loss per share was -0.17.
| Revenue | 332.21M |
| Gross Profit | 153.59M |
| Operating Income | 3.40M |
| Pretax Income | -24.19M |
| Net Income | -17.44M |
| EBITDA | 49.79M |
| EBIT | 3.40M |
| Loss Per Share | -0.17 |
Balance Sheet
The company has 192.07 million in cash and 70.09 million in debt, giving a net cash position of 129.57 million or 1.28 per share.
| Cash & Cash Equivalents | 192.07M |
| Total Debt | 70.09M |
| Net Cash | 129.57M |
| Net Cash Per Share | 1.28 |
| Equity (Book Value) | 761.89M |
| Book Value Per Share | 7.53 |
| Working Capital | 271.96M |
Cash Flow
In the last 12 months, operating cash flow was 62.50 million and capital expenditures -1.73 million, giving a free cash flow of 60.77 million.
| Operating Cash Flow | 62.50M |
| Capital Expenditures | -1.73M |
| Free Cash Flow | 60.77M |
| FCF Per Share | 0.60 |
Margins
Gross margin is 46.23%, with operating and profit margins of 1.02% and -5.25%.
| Gross Margin | 46.23% |
| Operating Margin | 1.02% |
| Pretax Margin | -7.28% |
| Profit Margin | -5.25% |
| EBITDA Margin | 14.99% |
| EBIT Margin | 1.02% |
| FCF Margin | 18.29% |
Dividends & Yields
Knight Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 7.58% |
| Shareholder Yield | 7.58% |
| Earnings Yield | -2.90% |
| FCF Yield | 10.47% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |